-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

-The Hindu   "The court has recognised the right of patients to access affordable medicines over profits for big pharma companies" It was celebration time for health activists and civil society groups after the Supreme Court delivered its judgment dismissing Swiss multinational company Novartis' appeal for patent for its anti-cancer medicine imatinib mesylate or Gleevec. "We are happy that the apex court has recognised the right of patients to access affordable medicines over profits...

-The Guardian In a village in India's poorest state, Bihar, farmers are growing world record amounts of rice – with no GM, and no herbicide. Is this one solution to world food shortages? Sumant Kumar was overjoyed when he harvested his rice last year. There had been good rains in his village of Darveshpura in north-east India and he knew he could improve on the four or five tonnes per hectare that he usually...

-The Telegraph Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched. But the court described its scheme of classifying people on the basis of their incomes as “too complicated” and again urged the company to reduce prices. Whatever the scheme, the end result...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....